Indivior Pays Out Over Blocking US Suboxone Rivals
Company Settles For $10m Over Frustrating Buprenorphine/Naloxone Generics
Executive Summary
Indivior has agreed to pay $10m to settle antitrust charges by the US Federal Trade Commission over its Suboxone brand.